It is the MAbs that have given a brand new approach for remediation towards a broad spectrum of diseases and it has been solely possible by the advancements of medicines towards the novel period of intrinsic therapy and these MAbs produced through hybridoma technologies are leading the path with domination. It has been more than 30 years since the initial MAbs were used clinically, as the time passed and through the use of cutting edge technologies now it has taken an industrial shape and the market value is calculated to be of billion dollars.
The MAbs are being widely used in many sectors. For example in genetic sequencing it is being used as a major tool. Same thing can be said for various biomedical researches too. Though having lots of potential advantages the hybridoma technology derived MAbs are not in a stalled state, researchers from all around the globe are trying heart and soul bearing in mind that the primary focus is to improve and invent new drug targets. By doing so the new generations of MAbs are being produced having maximum efficiency and applications in the clinical field.